Pharis Mohideen
Chief Tech/Sci/R&D Officer chez DBV TECHNOLOGIES
Fortune : 119 544 $ au 29/02/2024
Profil
Presently, Pharis Mohideen is Chief Medical Officer for DBV Technologies SA.
He previously held the position of Principal at Bristol Myers Squibb Co., Chief Medical Officer of Millendo Therapeutics US, Inc., Chief Medical Officer at Millendo Therapeutics, Inc., Senior Director at Novartis International AG, Global Head-Clinical Program at Novartis Oncology, Inc., Vice President-Clinical Development at Shionogi, Inc. and Assistant Professor-Medicine at the University of Hawai'i at Hilo.
He received a doctorate, a graduate degree and an undergraduate degree from the University of Hawai'i at Hilo and a graduate degree from Vanderbilt University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
DBV TECHNOLOGIES SA
0,09% | 22/11/2023 | 82 194 ( 0,09% ) | 119 544 $ | 29/02/2024 |
Postes actifs de Pharis Mohideen
Sociétés | Poste | Début |
---|---|---|
DBV TECHNOLOGIES | Chief Tech/Sci/R&D Officer | 22/07/2019 |
Anciens postes connus de Pharis Mohideen
Sociétés | Poste | Fin |
---|---|---|
MILLENDO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 12/07/2019 |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Corporate Officer/Principal | 01/10/2014 |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01/01/2012 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/2008 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Pharis Mohideen
Vanderbilt University | Graduate Degree |
University of Hawai'i at Hilo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
DBV TECHNOLOGIES | Health Technology |
Entreprise privées | 5 |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |